A phase 2 randomized trial (PEMBRO-RT) demonstrated that SABR prior to pembrolizumab treatment for locally advanced NSCLC was well tolerated, with programmed death ligand (PD-L1)–negative patients showing significantly improved prognosis (45). The gene discussed is CD274; the disease is non-small cell lung carcinoma.